根据一份提交给美国证券交易委员会（SEC）的文件，生物技术公司Atara Biotherapeutics可能于2026年5月12日发行价值高达7927万美元的普通股。此次潜在的股票发行旨在为公司筹集资金，具体细节已在监管文件中披露。
根据一份提交给美国证券交易委员会（SEC）的文件，生物技术公司Atara Biotherapeutics可能于2026年5月12日发行价值高达7927万美元的普通股。此次潜在的股票发行旨在为公司筹集资金，具体细节已在监管文件中披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.